Tissue Genesis, LLC Provides Cell Isolation Processing for Patients with Critical Limb Ischemia (CLI) in Ukrainian Clinical Study

Study to investigate whether adipose-derived SVF therapy can reduce amputation, speed up wound healing and increase ambulatory function.

HOUSTON (March 26, 2019) — Tissue Genesis, LLC, the leading provider of cell isolation technology is pleased to announce that the Icellator® is being used to generate therapeutic cell preparations at the V.P. Komisarenko Institute of Endocrinology and Metabolism in Kiev, Ukraine, for patients with critical limb ischemia (CLI). The autologous stem-cell therapy, which utilizes a patient’s own fat cells, is the first of its kind in Ukraine to treat CLI patients. This effort will build on previous stem cell studies that have shown promising results as a potential therapeutic option for this debilitating and increasingly common vascular disease.

Read more

TG & Human Life CORD, Japan Announce Exclusive Partnership

HOUSTON (Nov. 1, 2017) – Human Life CORD Japan, Inc., (HLC) a group company of Nihon Trim (Cord No. 6788, Tokyo Stock Exchange 1st Section) is pleased to announce a strategic agreement with Tissue Genesis, LLC (TG) to distribute its proprietary stem cell processing products in commercial clinics, research institutions, and hospitals in Japan and China. Read more